Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 20:17:2119-2135.
doi: 10.2147/DDDT.S411829. eCollection 2023.

Bibliometric Analysis of Global Trends in Remimazolam-Related Research Over the Past 15 Years: Compared with Propofol

Xinyue Hu  1 , Beibei Wang  1 , Li Hu  1 , Dong Han  1 , Jing Wu  1
Affiliations

Bibliometric Analysis of Global Trends in Remimazolam-Related Research Over the Past 15 Years: Compared with Propofol

Xinyue Hu et al. Drug Des Devel Ther. .

Abstract

Purpose: Although remimazolam is a popular novel anesthetic, there is a lack of data in the literature about current and future trends. Therefore, the aim of this study was to explore emerging trends and potential hotspots of remimazolam research over the past 15 years through bibliometric methods.

Methods: Relevant articles on remimazolam published from 2007 to 2022 and propofol from 1997 to 2001 were retrieved from the Web of Science Core Collection database. Data were collected using Microsoft Excel and graphs were generated with the Bibliometrix package in R software. Visual bibliometric maps were created using VOS viewer and CiteSpace software.

Results: In total, 184 articles were included for analysis. Remimazolam-related research tended to increase, especially from 2020 to 2022. China produced the most publications (327), whereas the USA dominated in quality (h-index = 16). Among institutions, PAION Deutschland GmbH produced the most articles (Np = 21). Similar to initial research and development of propofol, the hotspots of remimazolam research have extended beyond pharmacokinetics and pharmacodynamics to adverse reactions, clinical scenarios, specific populations, and compatible regimens, as confirmed by high numbers of common references and keywords.

Conclusion: Remimazolam research has developed rapidly over the past two years. Remimazolam can achieve faster onset and recovery, and more stable hemodynamics than midazolam or propofol, enabling gradual piloting of applications from endoscopy and general anesthesia to sedation of critical care patients; foreseeing specific population (patients with hepatic or renal impairment and reduced cardiovascular reserve, the elderly, and children) through compatible anesthetics regimens to more optimal and safe. Future studies of remimazolam are likely to include adverse reactions, effects on different organ systems, and identification of monitoring indicators.

Keywords: CNS 7056; applications; bibliometric analysis; remimazolam; research trends; specific population.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Trends in the Np annually and cumulatively.
Figure 2
Figure 2
Remimazolam-related articles published from 2007 to 2022 by countries/regions.
Figure 3
Figure 3
Top 10 countries/regions with the most remimazolam-related articles published from 2007 to 2022.
Figure 4
Figure 4
Co-occurrence network among 14 countries/regions.
Figure 5
Figure 5
Institutions with ≥ 4 remimazolam-related articles published from 2007 to 2022.
Figure 6
Figure 6
Top journals with the most remimazolam-related articles.
Figure 7
Figure 7
(A) A co-occurrence network of the top 14 authors in terms of citations. (B) A time graph of remimazolam-related articles by author.
Figure 8
Figure 8
Co-occurrence clusters of the top 50 keywords related to remimazolam.
Figure 9
Figure 9
Co-occurrence clusters of the top 99 keywords related to propofol.
Figure 10
Figure 10
(A) Co-citation graph of remimazolam-related articles. (B) Cluster network graph of the remimazolam-related articles. (C) Top 10 references with the strongest citation bursts.
Figure 11
Figure 11
Cluster network graph of references in propofol-related articles.
Figure 12
Figure 12
Timeline graph of keywords.
Figure 13
Figure 13
Keywords with the strongest citation bursts.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056: a Novel Ultra–short-acting benzodiazepine. Anesthesiology. 2007;107(1):60–66. doi:10.1097/01.anes.0000267503.85085.c0 - DOI - PubMed
    1. Keam SJ. Remimazolam: first Approval. Drugs. 2020;80(6):625–633. doi:10.1007/s40265-020-01299-8 - DOI - PubMed
    1. Chen Y, Jin Q, Fang H, et al. Analytic network process: academic insights and perspectives analysis. J Clean Prod. 2019;235:1276–1294. doi:10.1016/j.jclepro.2019.07.016 - DOI
    1. Ninkov A, Frank JR, Maggio LA. Bibliometrics: methods for studying academic publishing. Perspect Med Educ. 2022;11(3):173–176. doi:10.1007/s40037-021-00695-4 - DOI - PMC - PubMed
    1. Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2005;2005:724–728. - PMC - PubMed